πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 88 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10406210

High-purity inhalable particles of insulin and insulin analogues, and high-efficiency meth

Amphastar Pharmaceuticals, Inc. Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10363288

Insulin mimotopes and methods of using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10322168

High-purity inhalable particles of insulin and insulin analogues, and high-efficiency meth

Amphastar Pharmaceuticals, Inc. Β· Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10258573

Micronized insulin and micronized insulin analogues prepared under acidic conditions, and

Amphastar Pharmaceuticals, Inc. Β· Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10188739

Compositions and methods for administering insulin or insulin-like protein to the brain

XENETIC BIOSCIENCES, INC. Β· Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10105414

Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal

Julius-Maximilians-Universitat Wurzburg Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9956178

Methods for delivering insulin preparations into a lumen of the intestinal tract using a s

Rani Therapeutics, LLC Β· Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9801938

Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists

FREISTAAT BAYERN REPRESENTED BY JULIUS-MAXIMILLIANS-UNIVERSITΓ„T WÜRZBURG Β· Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9676846

Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9657096

Human domain antibodies against components of the human insulin-like growth factor (IGF) s

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9624472

Production of insulin producing cells

Regents of the University of Minnesota Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9623055

Method for preventing and/or treating insulin resistance

ACADEMISCH MEDISCH CENTRUM Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9592265

Modulation of oxidative stress, inflammation, and impaired insulin sensitivity with grape

The Regents of the University of California Β· Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9457065

Methods for delivering insulin preparations into a lumen of the intestinal tract using a s

Rani Therapeutics, LLC Β· Granted Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9433650

Method for preventing and/or treating insulin resistance

ACADEMISCH MEDISCH CENTRUM Β· Granted Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9150644

Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9127056

Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth fact

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9101601

Methods of treating or preventing insulin resistance and associated diseases and condition

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9085757

Production of insulin producing cells

Regents of the University of Minnesota Β· Granted Tue Jul 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9056907

Human domain antibodies against components of the human insulin-like growth factor (IGF) s

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8993633

Treatment of muscle disease characterized by insulin resistance

Fate Therapeutics, (Canada) Inc. Β· Granted Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8900555

Insulin derivative formulations for pulmonary delivery

Nektar Therapeutics Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8858950

Delivery of pharmaceutical agents via the human insulin receptor

The Regents of the University of California Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8809269

Therapeutic agent preparations comprising insulin for delivery into a lumen of the intesti

Rani Therapeutics, LLC Β· Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted